Trials / Completed
CompletedNCT00532116
PK Comparison of 6mg and 12mg EMSAM in Elderly vs. Non-Elderly
Pharmacokinetic Comparison of the 6mg/24hr and 12mg/24hr EMSAM (Selegiline Transdermal System) in Healthy Elderly and Non-Elderly Volunteers
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Somerset Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Evaluate the effect of age on the PK of two different doses of EMSAM.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EMSAM (Selegiline Transdermal System) 6mg | STS 6mg/24hr |
| DRUG | EMSAM (Selegiline Transdermal System) 12mg | EMSAm 12mg/24Hr |
Timeline
- Start date
- 2007-04-01
- Completion
- 2007-08-01
- First posted
- 2007-09-19
- Last updated
- 2007-09-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00532116. Inclusion in this directory is not an endorsement.